{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"69.5","value":"56.4"},{"groupId":"OG001","lowerLimit":"44.7","upperLimit":"68.3","value":"56.5"},{"groupId":"OG002","lowerLimit":"31.5","upperLimit":"44.9","value":"38.2"},{"groupId":"OG003","lowerLimit":"19.1","upperLimit":"59.1","value":"39.1"},{"groupId":"OG004","lowerLimit":"28","upperLimit":"78.6","value":"53.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"199"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"15"}],"units":"Participants"}],"description":"Overall survival estimate at 4 years post BMT","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.\n\nbusulfan: Given IV\n\ncyclophosphamide: Given IV","id":"OG000","title":"BuCy"},{"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"OG001","title":"CyTBI"},{"description":"Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV","id":"OG002","title":"FluMel"},{"description":"Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"OG003","title":"VpCyTBI"},{"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1. OR Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3. OR Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4. OR Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2. OR Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.","id":"OG004","title":"Other"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4-year","title":"4 yr OS","type":"SECONDARY","unitOfMeasure":"percentage of participants"}